Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.

Hiatt WR, Hirsch AT, Creager MA, Rajagopalan S, Mohler ER, Ballantyne CM, Regensteiner JG, Treat-Jacobson D, Dale RA, Rooke T.

Vasc Med. 2010 Jun;15(3):171-9. doi: 10.1177/1358863X09360579. Epub 2010 Mar 8.

PMID:
20212073
2.

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.

Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD.

Am J Cardiol. 2002 Mar 15;89(6):672-8.

PMID:
11897208
3.

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR; ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation.

Am J Cardiol. 2003 Mar 15;91(6):667-72.

PMID:
12633795
4.

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.

Insull W Jr, McGovern ME, Schrott H, Thompson P, Crouse JR, Zieve F, Corbelli J.

Arch Intern Med. 2004 May 24;164(10):1121-7.

PMID:
15159270
6.

A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.

Hunninghake DB, McGovern ME, Koren M, Brazg R, Murdock D, Weiss S, Pearson T.

Clin Cardiol. 2003 Mar;26(3):112-8.

7.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310
8.

Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.

Rubenfire M; Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group.

Am J Cardiol. 2004 Aug 1;94(3):306-11.

PMID:
15276093
9.

Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.

Kawata AK, Revicki DA, Thakkar R, Jiang P, Krause S, Davidson MH, Punzi HA, Padley RJ.

Clin Drug Investig. 2009;29(4):215-29. doi: 10.2165/00044011-200929040-00001.

PMID:
19301936
10.

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.

Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.

Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.

PMID:
20152243
11.

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D.

Int J Clin Pract. 2010 May;64(6):727-38. doi: 10.1111/j.1742-1241.2010.02370.x.

PMID:
20518948
12.

Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.

Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA.

Arch Intern Med. 1994 Jul 25;154(14):1586-95.

PMID:
8031206
13.

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT.

N Engl J Med. 1990 Nov 8;323(19):1289-98.

14.

[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].

Li XP, Duan J, Zhao SP, Tan MY, Xu ZM, Zhang DQ.

Zhonghua Yi Xue Za Zhi. 2006 Sep 12;86(34):2399-403. Chinese.

PMID:
17156651
15.

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.

Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM.

Am J Cardiol. 1998 Sep 15;82(6):737-43.

PMID:
9761083
16.

A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.

Brass EP, Cooper LT, Morgan RE, Hiatt WR.

J Vasc Surg. 2012 Feb;55(2):381-389.e1. doi: 10.1016/j.jvs.2011.09.004. Epub 2011 Nov 25.

17.

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group.

Arch Intern Med. 2002 Jul 22;162(14):1568-76.

PMID:
12123399
18.

Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.

Gardner SF, Schneider EF, Granberry MC, Carter IR.

Pharmacotherapy. 1996 May-Jun;16(3):419-23.

PMID:
8726600
19.

A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin.

Davidson MH, Lukacsko P, Sun JX, Phillips G, Walters E, Sterman A, Niecestro R, Friedhoff L.

Clin Ther. 2002 Jan;24(1):112-25.

PMID:
11833826

Supplemental Content

Support Center